Oragenics Reports Director/Officer Changes & Financials
Ticker: OGEN · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1174940
Sentiment: neutral
Topics: management-change, financials, corporate-governance
TL;DR
Oragenics filed an 8-K detailing director/officer changes and financial statements.
AI Summary
Oragenics, Inc. filed an 8-K on December 15, 2025, reporting events as of December 11, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in leadership and executive compensation at Oragenics, Inc., which could impact the company's strategic direction and operational focus.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with the filing of financial statements, can signal significant internal shifts or financial performance that may affect the company's stock.
Key Players & Entities
- Oragenics, Inc. (company) — Registrant
- December 11, 2025 (date) — Earliest event reported
- December 15, 2025 (date) — Filing date
FAQ
What specific directors or officers departed from Oragenics, Inc. as reported in this 8-K?
The filing indicates the departure of directors or certain officers, but does not name specific individuals in the provided text.
Who were elected as new directors or appointed as officers for Oragenics, Inc.?
The filing states the election of directors and appointment of certain officers, but specific names are not detailed in the provided text.
Are there any details on the compensatory arrangements for Oragenics, Inc.'s officers included in this filing?
The filing mentions compensatory arrangements of certain officers, but the specifics are not provided in the excerpt.
What is the primary business of Oragenics, Inc. according to the SIC code?
Oragenics, Inc. is classified under Pharmaceutical Preparations with SIC code 2834.
When is Oragenics, Inc.'s fiscal year end?
Oragenics, Inc.'s fiscal year ends on December 31.
Filing Stats: 738 words · 3 min read · ~2 pages · Grade level 12.5 · Accepted 2025-12-15 16:05:35
Key Financial Figures
- $325,000 — nt (5%) in her annual base salary, from $325,000 to $341,250, effective January 1, 2026.
- $341,250 — er annual base salary, from $325,000 to $341,250, effective January 1, 2026. Additionall
- $110,500 — termined she was entitled to a bonus of $110,500. Award of Stock Options . On December
- $0.93 — ed (the "Plan") at an exercise price of $0.93 per share, the closing price on the Dec
- $30,000 — res of Company common stock equating to $30,000 with an exercise price set as the closi
Filing Documents
- form8-k.htm (8-K) — 43KB
- 0001493152-25-027745.txt ( ) — 205KB
- ogen-20251211.xsd (EX-101.SCH) — 3KB
- ogen-20251211_lab.xml (EX-101.LAB) — 33KB
- ogen-20251211_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 15 th day of December 2025. ORAGENICS, INC. (Registrant) BY: /s/ Janet Huffman Janet Huffman Chief Executive Officer